Camagüey, January 4th. – The PORVAC, classical swine fever (CSF) and GAVAC vaccine, produced by the Center for Genetic Engineering and Biotechnology (CIGB) in the province of Camagüey, reinforced its presence on the national market in 2018.
More than a million cattle across the country benefited from the use of GAVAC antigen designed in this integrated Rhipicephalus (boophilus) microplus control plant, the most common in Cuban paddocks, as confirmed by Cuban News Agency Nemesio González Fernández, CIGB Director General -And.
By the end of 2018, more than two million 600,000 vaccine doses were commercialized across the state, which is higher than the previous year, as part of a multisectoral strategy involving the Ministry of Agriculture, the Ministry of Agriculture and CIGB. Department of Animal Health and other subjects.
In the case of PORVAC, whose large-scale production at the Camagüey Biotechnology Center began in the recently completed year, is already present in the genetic units and multiplicators of the pig industry in all provinces, and is supplied in a pyramid scheme.
It is expected that by 2019, the distribution of 1.2 million doses of this subunit vaccine, obtained from a combination of virus and pig protein, will be achieved by 2019, and will be more effective and safer than those of the attenuated virus that exists in the market, González Fernández noted.
In the year 2018, more than 954,600 doses of PORVAC have been sold, which also destroys the vertical transmission of viruses from the mother to the progeny, which gives PORVAC a high added value, more if it says that PPC is one of the diseases that causes more damage to the global pig industry.
In 2019, CIGB Camaguey intends to further strengthen the presence of its products on the national market and attract investments to improve installed technological capacities. (ACN) (photo: archive)